The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
The effects of the synthetic cannabinoid receptor agonist WIN 55,212-2 on dopamine receptor-mediated alleviation of akinesia were evaluated in the reserpine-treated rat model of parkinsonism. The dopamine D2 receptor agonist quinpirole (0.1 mg/kg, ip) caused a significant alleviation of the akinesia. This effect was significantly reduced by coinjection with the cannabinoid receptor agonist WIN 55,212-2 (0.1 and 0.3 mg/kg). The simultaneous administration of the cannabinoid receptor antagonist SR 141716A (3 mg/kg, ip) with quinpirole and WIN 55,212-2 blocked the effect of WIN 55,212-2 on quinpirole-induced alleviation of akinesia. The selective dopamine D1 receptor agonist chloro-APB (SKF82958, 0.1 mg/kg) alleviated akinesia in a significant manner. WIN 55,212-2 (0.1-1 mg/kg, ip) did not affect the antiakinetic effect of chloro-APB. Combined injection of both D1 and D2 dopamine receptor agonists (both at either 0.1 or 0.02 mg/kg) resulted in a marked synergism of the antiakinetic effect. WIN 55,212-2 (0.1-1 mg/kg) significantly reduced the antiakinetic effect of combined injections of quinpirole and chloro-APB at both 0.1 and 0.02 mg/kg. The effect of 0.3 mg/kg WIN 55,212-2 on combined D1 and D2 agonist-induced locomotion (0.02 mg/kg) was blocked by SR 141761A (3 mg/kg). Neither WIN 55,212-2 alone (0.1 and 0.3 mg/kg) nor SR 141716A (3 and 30 mg/kg) alone had an antiparkinsonian effect. These results suggest that cannabinoids may modulate neurotransmission in the pathway linking the striatum indirectly to basal ganglia outputs via the lateral globus pallidus and the subthalamic nucleus.
Maneuf
Y P
YP
Division of Neuroscience, School of Biological Sciences, University of Manchester, United Kingdom. ymaneuf@fs2.scg.man.ac.uk
Crossman
A R
AR
Brotchie
J M
JM
D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000503:physiopathology; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D048588:Benzoxazines; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D008124:Locomotion / Q000187:drug effects; D008297:Male; D009025:Morpholines / Q000494:pharmacology / Q000633:toxicity*; D009281:Naphthalenes / Q000494:pharmacology / Q000633:toxicity*; D009419:Nerve Tissue Proteins / Q000187:drug effects* / Q000502:physiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D019257:Quinpirole / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid; D017447:Receptors, Dopamine D1 / Q000187:drug effects* / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000502:physiology; D011955:Receptors, Drug / Q000819:agonists*; D012110:Reserpine / Q000633:toxicity*; D000077285:Rimonabant; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D001552:Benzazepines; D048588:Benzoxazines; D018491:Dopamine Agonists; D009025:Morpholines; D009281:Naphthalenes; D009419:Nerve Tissue Proteins; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D011955:Receptors, Drug; D019257:Quinpirole; D005680:gamma-Aminobutyric Acid; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C071262:SK&F 82958; D012110:Reserpine; D000077285:Rimonabant